1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Novo Nordisk A/S

Novo Nordisk A/S

NOVO.TO
Novo Nordisk A/SCA flagToronto Stock Exchange
16.12
CAD
-0.20
- -
53.94BMarket Cap

Total Valuation

Novo Nordisk A/S carries a market capitalization of 53.94B, placing it among publicly traded companies globally. Its enterprise value stands at 516.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap53.94B
Enterprise Value516.53B

Share Statistics

Novo Nordisk A/S currently has 4.42B shares outstanding.

Shares Outstanding4.42B
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Novo Nordisk A/S trades at a trailing price-to-earnings ratio of 3.63. The price-to-sales ratio is 1.28, and the price-to-book ratio stands at 1.90.

PE Ratio3.63
PS Ratio1.28
PB Ratio1.90
P/TBV Ratio4.25
P/FCF Ratio1.96
P/OCF Ratio3.21

Enterprise Valuation

On an enterprise value basis, Novo Nordisk A/S trades at an EV/EBITDA multiple of 3.19 and an EV/FCF ratio of 2.39. The EV/Sales ratio of 1.57 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 3.64 provides insight into valuation relative to core operating earnings.

EV / Sales1.57
EV / EBITDA3.19
EV / EBIT3.64
EV / FCF2.39

Financial Position

Novo Nordisk A/S maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.33, indicating elevated leverage, while an interest coverage ratio of 273.09 demonstrates strong ability to service its debt obligations.

Current Ratio0.87
Quick Ratio0.64
Debt / Equity63.33
Debt / EBITDA0.87
Interest Coverage273.09

Financial Efficiency

Novo Nordisk A/S posts a return on equity of 59.82 and a return on invested capital of 33.40.

Return on Equity (ROE)59.82
Return on Assets (ROA)21.62
Return on Invested Capital (ROIC)33.40
Return on Capital Employed (ROCE)37.19
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.31

Taxes

Over the trailing twelve months, Novo Nordisk A/S has paid 32.31B in income taxes, reflecting an effective tax rate of 21.72.

Income Tax32.31B
Effective Tax Rate21.72

Stock Price Statistics

Novo Nordisk A/S's stock has declined approximately -15.69038% over the past 52 weeks. The 50-day moving average sits at 19.04, while the 200-day moving average is 19.27.

Beta (5Y)N/A
52-Week Price Change-15.69038%
50-Day Moving Average19.04
200-Day Moving Average19.27
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Novo Nordisk A/S generated 329.43B in revenue and converted that into 116.44B in net income, yielding earnings per share of 26.20. EBITDA reached 161.94B, while operating income came in at 142.10B.

Revenue329.43B
Gross Profit265.68B
Operating Income142.10B
Pretax Income148.75B
Net Income116.44B
EBITDA161.94B
EBIT142.10B
Earnings Per Share (EPS)26.20

Balance Sheet

Novo Nordisk A/S holds 44.98B in cash and equivalents against 140.13B in total debt, resulting in a net debt position of 95.65B. Total book value stands at 221.28B, with working capital of -30.39B providing operational flexibility.

Cash & Cash Equivalents44.98B
Total Debt140.13B
Net Debt95.65B
Equity (Book Value)221.28B
Book Value Per Share50.01
Working Capital-30.39B

Cash Flow

Novo Nordisk A/S produced 131.88B in operating cash flow over the past twelve months. After subtracting -84.09B in capital expenditures, free cash flow totaled 47.79B - equivalent to 10.76 per share.

Operating Cash Flow131.88B
Capital Expenditures-84.09B
Free Cash Flow47.79B
FCF Per Share10.76

Margins

Novo Nordisk A/S operates with a gross margin of 80.65, reflecting its pricing power and cost economics. The operating margin of 43.13 and net profit margin of 35.35 provide insight into operational efficiency.

Gross Margin80.65
Operating Margin43.13
Pretax Margin45.15
Profit Margin35.35
EBITDA Margin49.16

Dividends & Yields

The company's payout ratio of 44.64 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share11.71
Dividend YieldN/A
Payout Ratio44.64
Shareholder Yield5.28
FCF Yield51.02

Scores

Novo Nordisk A/S posts an Altman Z-Score of 2.95, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.95